Syros Pharmaceuticals. has filed a patent for a method of treating cancer by administering compounds of Formula (I) targeting CDK7. The invention aims to inhibit CDK7 activity in patients with solid tumors, potentially offering a new treatment option for cancer. GlobalData’s report on Syros Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Syros Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Syros Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Syros Pharmaceuticals's grant share as of January 2024 was 24%. Grant share is based on the ratio of number of grants to total number of patents.

Treating cancer with compound of formula (i)

Source: United States Patent and Trademark Office (USPTO). Credit: Syros Pharmaceuticals Inc

A patent application (Publication Number: US20240034742A1) discloses a method for treating cancer characterized by the presence of a solid tumor and overexpression or aberrant activity of CDK7. The method involves administering a pharmaceutical composition containing a compound of Formula (I). The cancer types that can be treated using this method include breast cancer, gastrointestinal tract cancer, lung cancer, pancreatic cancer, reproductive organ cancer, bone cancer, or soft tissue cancer. The dosage of the compound is specified to be about 1-10 mg/day.

Furthermore, the method includes treating cancer cells that exhibit elevated CDK7 expression, resistance to previous anti-cancer agents, or overexpression of hormone receptors. The patent also covers cases where the cancer has become resistant to specific treatments like CDK4/6 inhibitors, Bcl-2 inhibitors, BET inhibitors, and others. The method allows for combination therapy with a second anti-cancer agent, including various inhibitors and therapeutic agents approved by regulatory agencies. Specific examples of second anti-cancer agents and their combinations for different cancer types are provided in the patent claims, offering a comprehensive approach to cancer treatment based on the identified molecular characteristics and resistance patterns of the cancer cells.

To know more about GlobalData’s detailed insights on Syros Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies